Background {#Sec1}
==========

Membranous ventricular septal aneurysm (MVSA) is an uncommon anomaly of the membranous portion of the cardiac septum. Aneurysmal bulging begins in a weak or incomplete cardiac septum that is unable to overcome the differential pressure between the left and right ventricles. MVSA occurs as an isolated abnormality or being associated with other cardiac malformations. MVSA is a well-recognized risk factor for outflow tract obstruction and embolisms, and is related (either directly or secondary to) to rupture, bacterial endocarditis, and arrhythmia. However, most patients with this cardiac anomaly were asymptomatic, and the aneurysms were discovered incidentally on echocardiography. Without diagnosis, unforeseen problems or unexpected deaths may occur in patients who are under a conditions of increased cardiovascular stress, such as pregnancy. The outcome of pregnancy and delivery in patients with MVSA has not been reported in the literature. We present 12 cases of pregnant women with incidentally discovered MVSA and discussed our experience in managing these cases.

Methods {#Sec2}
=======

This was a retrospective study approved by the Institutional Review Board of West China Second University Hospital. We reviewed the medical records of 591 pregnant women with congenital heart disease (CHD) who were admitted at West China Second University Hospital, a tertiary referral center, between May 2008 and March 2015. Prevalence of CHD in pregnancy was 0.88% (591/66988). Among 591 pregnant women with CHD, 12 cases of MVSA (2.03%) were diagnosed.

Patient characteristics {#Sec3}
-----------------------

The age of 12 pregnant women with MVSA ranged from 17 to 34 years old. All patients underwent clinical physical examination, electrocardiography (ECG), and transthoracic echocardiography. The co-morbidities of hypertension, diabetes mellitus, and other pregnancy associated significant conditions were also recorded and analyzed in the current study.

Echocardiography {#Sec4}
----------------

All included patients were evaluated by echocardiography. MVSA was diagnosed when the protrusion in the echocardiographic evaluation exceeded 7.5 mm \[[@CR1]\]. The range of the protrusion, the mobility of the aneurismal structure, the size of the defect, left ventricular systolic function and the presence of other heart abnormalities were measured. Color flow Doppler was used to evaluate for the presence of septal shunt and valvular regurgitation, and to assess pulmonary artery pressure gradients. The left atrial/ventricular size or diameter was assessed in the transverse dimension in the parasternal longitudinal view (M-mode) and calculated planimetrically in the apical four-chamber view (2D). If mural thrombus was suspected, further echocardiographic evaluation was performed.

Electrocardiogram {#Sec5}
-----------------

24-h ambulatory ECGs were performed in patients when they had abnormal electrocardiographic pattern; or in patients with abnormal electrolyte that might increase susceptibility to arrhythmia.

Other examinations {#Sec6}
------------------

MRI was used to confirm ischemic stroke. Vascular ultrasound was performed for patient with suspected peripheral embolism. Central venous catheterization (CVT) and/or right heart catheterization was undertaken to monitor central venous pressure (CVP) and pulmonary artery pressure gradients in patients who had signs of pulmonary hypertension.

Results {#Sec7}
=======

Cardiac complications {#Sec8}
---------------------

Eight cases of MVSA, heart disease was initially diagnosed during pregnancy. Five of these patients presented with chest tightness and shortness of breath at the second trimester. Three asymptomatic cases were found on the basis of systolic murmurs upon ausculation, and confirmed by echocardiography during the second trimester. In the remaining 4 cases (33.3%), diagnosis was made for the first time during labour. Cardiographic characteristics of the mothers are summarized in Table [1](#Tab1){ref-type="table"}. Nine (75%) cases had cardiac function NYHA class III or higher. Five cases (41.7%) of MVSA existed in isolation, and 7 (58.3%) cases were complicated with ventricular septal defect.Table 1Characteristics of echocardiography and electrocardiogram in pregnant woman with MVSANo.Type of heart diseaseLA/LV diameter (mm)NYHA-FCRange of protrusion\
(mm)Size of the defect\
(mm)PH^\*^Valve conditionMural thrombusLVSD^\*^Arrhythmia1VSANormalII13 × 13No breakNoneTR^\*^NoneEF = 59%, FS = 31%--2VSA\
VSD\*NormalIII15 × 115NoneNormalNoneEF = 57%, FS = 30%--3VSA\
VSDNormalIII16 × 1511ModerateTRNoneEF = 71%, FS = 41%Sinus tachycardia4VSA\
VSDLA = 38, LV = 52III9 × 85MildMR\*NoneEF = 59%, FS = 33%--5VSA\
VSD\
PDA\*NormalIII17 × 125MildMR + TRNoneEF = 60%, FS = 32%Sinus tachycardia6VSA\
VSDLA = 35, LV = 58III14 × 1111ModerateNormalNoneEF = 58%, FS = 31%Sinus rhythm with extreme right axis deviation (+85°)7VSA\
VSDLA = 33, LV = 50III14 × 147ModerateTRNoneEF = 64%, FS = 34%--8VSALA = 46, LV = 57III-IV28 × 14No breakMildMR + TRNoneEF = 30%, FS = 14%I°AVB, VPB9VSA\
VSDLA = 38, LV = 57IV20 × 158SevereTRNoneEF = 59%, FS = 32%IRBBB10VSANormalII12 × 124NoneNormalNoneEF = 71%, FS = 40%Sinus tachycardia11VSANormalIII16 × 10No breakNoneMR + TRNoneEF = 63%, FS = 34%Sinus arrhythmia, APB12VSANormalI--II8 × 8No breakNoneNormalNoneEF = 69%, FS = 39%--*VSD* ventricular septal defect, *PDA* patent ductus arteriosus, *PFO* patent foramen ovale, *NYHA-FC* cardiac function grading (New York Heart Association), *PH* pulmonary hypertension, *LVSD* left ventricular systolic function, *LA/LV* Left atrial/ventricular, *MR* mitral regurgitation, *TR* tricuspid regurgitation, *AVB* atrioventricular block, *IRBBB* incomplete right bundle branch block, *VPB* ventricular premature beat, *APB* atrial premature beat

Upon diagnosis, the diameter of MVSA ranged from 8 mm to 28 mm (mean ± SD: 13.54 ± 4.31) and the protrusion area from 8 × 8 mm to 28 × 14 mm). Among them, 6 cases had a diameter greater than 15 mm. The aneurysm remained intact in 4 cases and was ruptured in 2 cases. Left cardiac diameter and left ventricular systolic function were assessed in all patients. Enlarged left heart chamber was found in 5 patients, and limited systolic function (EF = 30%, FS = 14%) was found in 1 patient.

In our study, the most common complications attributable to MVSA were pulmonary arterial hypertension (PAH) (58.3%), atrioventricular valve diseases (66.7%) and arrhythmias (58.3%). No thromboembolism was found in our cases. There were 3 cases (25%) of mild PAH, 3 cases (25%) of moderate PAH and 1 case (8.3%) of severe PAH. Eight patients had tricuspid and/or mitral regurgitation but none of them developed stenosis. According to ECG, one patient had 1st-degree ventricular premature beats (I AVB) and ventricular premature beats (VPB). One patient had atrial premature beats (APB); 3 patients had sinus tachycardia, and 1 patient had incomplete right bundle branch block.

Obstetric complications {#Sec9}
-----------------------

The clinical data of obstetric complications, maternal mortality and fetal/neonatal outcome are shown in Table [2](#Tab2){ref-type="table"}. One case (NYHA class IV with severe pulmonary hypertension) had to terminate pregnancy at 17 weeks because of cardiogenic shock. She was then transferred to the Department of Cardiology for further treatments. Obstetric complications were found in 9 (81.8%) patients, including premature labor, premature rupture of membranes (PROM), preeclampsia, breech presentation, gestational diabetes mellitus (GDM), and postpartum hemorrhage resulting from twin pregnancy and placenta praevia. All cases had elective cesarean sections. Eight patients received combined spinal-epidural anesthesia, 1 epidural anesthesia, and 2 patients general anesthesia.Table 2Obstetrics characteristics of pregnancy complicated with MVSANo.AgeBMIGravidity and parity historyObstetric complicationMode and time of deliveryAnesthesia methodsApgar Score\
(1--5-10 min)OutcomesHOD\
(day)Antibiotics and day uses12926.56G1P0NoneCaesarean section:\
38 + 2 weeksCombined spinal epidural10--10-10M -- good\
N -- live, 3175 g6Ceftezole (5d)21725.08G1P0Prematurity, Preeclampsia Breech presentationCaesarean section:\
31 + 1 weeksEpidural anesthesia10--10-10M -- good\
N -- live, 2050 g,with PDA and PFO9Cefoxitin (2.5d)33227.04G3P1GDMCaesarean section:\
37 weeksGeneral anesthesia10--10-10M -- good\
N -- live, 3250 g6Cefoxitin (5d)43324.22G2P0Prematurity, PROMCaesarean section:\
34 + 1 weeksCombined spinal epidural9--10-10M -- good\
N -- live, 2200 g12Cefmetazole (12d)52423.37G2P0NoneCaesarean section:\
39 + 2 weeksCombined spinal epidural10--10-10M -- good\
N -- live, 3600 g4Cefoxitin (2d)62122.60G1P0Prematurity, Moderate anemiaCaesarean section:\
33 + 6 weeksGeneral anesthesia8--9-10M -- good\
N -- live, 2180 g10Cefoxitin (7d)71919.56G1P0PrematurityCaesarean section:\
34 weeksCombined spinal epidural8--9-10M -- good\
N -- live, 2260 g8Piperacillin- tazobactam (7d)82518.43G1P0NoneTerminate pregnancy:\
17 weeksCombined spinal epiduralNoneM -- Cardiac shock, transferred to the Department of Cardiology\
N -- died, 80 g3Ceftriaxone(2d)91920.30G1P0PrematurityCaesarean section:\
30 + 4 weeksGeneral anesthesia4--5-8M -- died with pulmonary infection and heart failure\
N -- live, 1095 g, SGA, died in the following day8Cefoxitin (2d)\
Meropene (5d)102925.20G2P0Prematurity, PROMCaesarean section:\
36 + 5 weeksCombined spinal epidural10--10-10M -- good\
N -- live,2930 g3Cefoxitin (2d)113023.44G5P1Prematurity, MCDA, Placenta praevia, Postpartum hemorrhageCaesarean section:\
34 + 4 weeksCombined spinal epiduralN1: 9--10-10M -- good, with pulmonary infection\
N (twins) -- 1: live, 1550 g, with SGA; 2: died, 2080 g, with TOF46Meropene (14d)\
Piperacillin tazobactam (7d)123426.53G6P1Breech presentationCaesarean section:\
38 + 5 weeksCombined spinal epidural10--10-10M -- good\
N -- live, 2800 g6Cefoxitin (2d)*VSD* ventricular septal defect, *PDA* patent ductus arteriosus, *BMI* body mass index (kg/cm^2^), *PROM* premature rupture of membranes, *GDM* gestational diabetes mellitus, *MCDA* monochorionic diamnionic twin, *M* maternal, *N* neonate, *PFO* patent foramen ovale, *TOF* Tetalogy of Fallot, *HOD* hospital day (total days in hospital)

Maternal and perinatal outcomes {#Sec10}
-------------------------------

In this study, 6 (50%) woman were primigravid (Table [2](#Tab2){ref-type="table"}). The case fatality rate in the study was 8.3% with death resulting from pulmonary infection and heart failure. Most neonates, 10 (76.9%) including a twin pregnancy had birth weights more than 2000 g but less than 2500 g. Three neonates (38.5%) weighed more than 2500 g. Neonatal case fatality rate was 15.4%. Congenital heart disease was noted in 2 babies (15.4%), one with TOF, and the other with PDA and PFO. The rate of small-for-gestational-age (SGA) (estimated infant weight after delivery below the 10th percentile for corresponding gestational age) was 15.4%.

Of note, maternal and neonatal mortality occurred only in patient with a MVSA protrusion diameter \> 15 mm and NYHA class III-IV. The maternal cardiac anomaly and the outcome of pregnancies are summarized in Table [3](#Tab3){ref-type="table"}.Table 3Outcome of pregnancies with different maternal cardiac anomalyParameter of anomalyNumber.of case\
(Fetal/maternal)PrematuritySGAFetal deathNeonatal deathMaternal deathTotal, n (%)13/127 (58.3%)2 (15.4%)1 (7.7%)2 (15.4%)1 (8.3%)Size of VSA  \< 10 mm2/21 (50%)0000 10--15 mm5/54 (80%)0000  \> 15 mm6/52 (40%)2 (33.3%)1 (16.7%)2 (33.3%)1 (16.7%)Defect of VSA Intact5/41 (25%)1 (20%)1 (20%)1 (20%)0  ≤ 5 mm4/43 (75%)0000  \> 5 mm4/43 (75%)1 (25%)01 (25%)1 (25%)LVSD Normal12/117 (63.6%)2 (16.7%)02 (16.7%)1 (8.3%) Dysfunction1/1001 (100%)00NYHA-FC I--II3/31 (33.3%)0000 III--IV10/ 96 (66.7%)2 (20%)1 (10%)2 (20%)1 (10%)PH None6/53 (60%)1 (16.7%)01 (16.7%)0 Mild3/31 (33.3%)01 (33.3%)00 Moderate3/32 (66.7%)0000 Severe1/11 (100%)1 (100%)01 (100%)1 (100%)Congenital abnormality None5/42 (50%)1 (20%)1 (20%)1 (20%)0 VSD7/75 (71.4%)1 (14.3%)01 (14.3%)1 (14.3%) PDA1/100000Valve condition Normal4/43 (75%)0000 TR4/42 (50%)1 (25%)01 (25%)1 (25%) MR1/11 (100%)0000 TR + MR4/31 (33.3%)1 (25%)1 (25%)1 (25%)0Arrhythmia None l5/53 (60%)0000 Sinus tachycardia4/42 (50%)0000 I°AVB1/1001 (100%)00 IRBBB1/11 (100%)1 (100%)01 (100%)1 (100%) Sinus tachycardia + APB2/11 (100%)1 (50%)01 (50%)0*NYHA-FC* cardiac function grading (New York Heart Association), *PH* pulmonary hypertension, *VSD* ventricular septal defect, *PDA* patent ductus arteriosus, *TR* tricuspid regurgitation, *MR* mitral regurgitation, *AVB* atrioventricular block, *IRBBB* incomplete right bundle branch block, *SGA* Small for gestational age

Discussion {#Sec11}
==========

Ventricular septal aneurysms are extremely rare clinicopathological entities that include congenital muscular interventricular septal aneurysm (CMISA) and membranous ventricular septal aneurysm (MVSA) \[[@CR2], [@CR3]\]. Membranous ventricular septal aneurysm was first described as a congenital malformation in 1826 by Laennec \[[@CR4]\]. It is thought that the membranous septum remains weak during embryonic development, and forms an aneurysm of the membranous septum---bulging toward the right under the pressure of left ventricle. It has also been proposed that MVSA could be acquired---the consequence of delayed natural closure of a ventricular septal defect after birth \[[@CR5]--[@CR7]\]. Indeed, MVSA is primarily associated with a history of spontaneous closure of a small membranous ventricular septal defect in childhood \[[@CR2]\]. Patients with MVSA may incur potential cardiac complications, such as aortic valve prolapse, right ventricular outflow obstruction, tricuspid valve insufficiency, arrhythmia, rupture, thromboembolism, and bacterial endocarditis \[[@CR8]--[@CR12]\]. However, most MVSA patients are asymptomatic, the physical examination and electrocardiogram may fail to identify MVSA in the absence of ventricular arrhythmia or other complications \[[@CR13]\]. MVSA may provide an occult cardiac source of cerebral or systemic embolus \[[@CR14]\]. Furthermore, congestive heart failure may occur because of adverse effects of MVSA on systolic function \[[@CR9]\].

Our subjects were asymptomatic before conception, or experienced mild symptoms, and physician did not pay enough attention to them. During pregnancy, the most common complications in our cases were pulmonary arterial hypertension, atrioventricular valve diseases and arrhythmia. No incidence of thromboembolism was found, and this may have assisted our clinical outcomes, which were basically good in spite of varied degrees of pulmonary arterial hypertension in 7 patients. The numbers of patients in the subgroups were too small to conduct further statistical analysis.

Asymptomatic patients with MVSA should be followed closely for potential cardiac complications. This is especially important for the cases in the setting of pregnancy \[[@CR15]--[@CR17]\]. Pregnancy places extra load on the heart, and can affect cardiac function, leading to increased maternal morbidity and perinatal morbidity \[[@CR18], [@CR19]\]. In general, women with NYHA class \> III have a relatively poor prognosis during pregnancy \[[@CR20]\]. In our study, one case with NYHA class IV and severe pulmonary hypertension had to terminate pregnancy at 17 weeks of gestation; and one case with NYHA class IV expired.

We assumed that pregnant women with MVSA were at risk for maternal and neonatal complications, although the outcome in pregnancy with MVSA has not been reported in the literature. There was indeed a high rate (\> 80%) of obstetric events involving prematurity, PROM, preeclampsia, breech presentation, GDM and postpartum hemorrhage. Mothers with CHD also have a high incidence of fetal complications such as miscarriage, premature births, low birth weights, respiratory distress syndrome, and cardiac anomalies \[[@CR21]\]. In this study, neonatal congenital heart disease (Tetralogy of Fallot) and SGA at birth (1550 g at 34 + 4 weeks, survived) occurred in a twin gestation, the former expired and the latter survived. An additional singleton baby was born with SGA (1095 g at 30 + 4 weeks gestation) and expired on day 2 post birth.

Due to high risk of complications during vaginal delivery, a cesarean section delivery is usually recommended for woman with cardiac disease, since extra cardiac burden from prolonged laboring process may be avoided \[[@CR17], [@CR22]\]. In the current study, except one terminated pregnancy in the second trimester, all of the remaining patients delivered by cesarean section under combined spinal epidural anesthesia, epidural anesthesia or general anesthesia. Except one maternal death from pulmonary infection and heart failure (also with severe pulmonary arterial hypertension, NYHA class IV), all other patients survived. Almost all of them suffered cardiac complications such as mild-to-moderate pulmonary arterial hypertension, atrioventricular valve diseases and arrhythmia, but none of them developed thromboembolism. The relative good outcomes in our patients may be at least partially owing to the absence of severe hypertension, cardiac failure and cerebral and pulmonary embolism. In addition, comprehensive interdisciplinary management among the cardiologist, obstetrician, anesthetist, and neonatologist, and detailed plans for delivery may have improved the prognosis \[[@CR23]\].

Conclusion {#Sec12}
==========

Pregnancy with MVSA presents an increased risk of cardiac complications. Maternal and neonatal risks seem to be associated with heart functional classification, pulmonary hypertension and history of serious cardiac arrhythmia. Accurate diagnosis and care by a multidisciplinary team should be the best approach in order to improve prognosis in these patients.

AVB

:   Atrioventricular block

CHD

:   Congenital heart disease

GDM

:   Gestational diabetes mellitus

IRBBB

:   Incomplete right bundle branch block

MVSA

:   Membranous ventricular septal aneurysm

NYHA-FC

:   Cardiac function grading (New York Heart Association)

PDA

:   Patent ductus arteriosus

PFO

:   Patent foramen ovale

PH

:   Pulmonary hypertension

PROM

:   Premature rupture of membranes

SGA

:   Small for gestational age

VPB

:   Ventricular premature beat

VSD

:   Ventricular septal defect
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